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JCancer survivors, the medical community, public health professionals, researchers, and policy-
makers all need information about newly diagnosed cancer cases and deaths to better understand
and address the disease burden. CDC collects cancer data on 96% of the U.S. population through the
National Program of Cancer Registries. The National Program of Cancer Registries routinely collects
data on all cancer occurrences, deaths, and the types of initial treatment received by the patients, and
recently CDC has made advances in its cancer surveillance activities that have direct applicability to
cancer survivorship research and care. This article examines CDC’s innovative uses of the National
Program of Cancer Registries infrastructure and data as a recruitment source for survivorship
research studies and behavioral interventions; comparative effectiveness and patient-centered
outcomes research; and the collection, consolidation, and dissemination of treatment summaries
for cancer survivors and their providers. This paper also discusses long-term, idealistic plans for
additional data linkages and sharing among public health, providers, and the cancer survivor
through innovative concepts such as patient portals and rapid-learning health care.
(Am J Prev Med 2015;49(6S5):S528–S535) Published by Elsevier Inc. on behalf of American Journal of
Preventive Medicine. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).IntroductionAsthe second leading cause of death, cancer posesa signiﬁcant public health challenge in the U.S.in terms of both mortality and morbidity.1
However, continuing progress in early diagnosis and
treatment has improved survival for many cancer
patients.2 In 1977, fewer than 4 million people in the
U.S. were living with a diagnosed cancer; in 2012, this
increased to about 13.7 million, and is expected to rise to
18 million by 2022 because of improved survival as well
as the growth and aging of the population.3
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shift beyond preventing cancer mortality to long-term
well-being. Cancer survivors, like the general population,
need to manage their health by participating in preven-
tive care; however, they also have unique needs related to
their diagnosis of cancer and its treatment. In 2005, IOM
released “From Cancer Patient to Cancer Survivor: Lost
in Transition,” a consensus report that highlights the fact
that many survivors ﬁnish their primary cancer therapy
unaware of their heightened health risks and ill-prepared
to manage their future healthcare needs.4 Furthermore,
delivery of recommended follow-up care is lacking, and
many of the unique psychosocial needs of survivors are
not routinely addressed.
Leveraging existing information on patient diagnosis
and care may help to address some survivorship needs.
Unbeknownst to most patients, cancer is a notiﬁable
disease, and collection of cancer registry data for public
health surveillance is mandated by law in all U.S. states or
jurisdictions. Hospitals, physicians’ ofﬁces, pathology
laboratories, and other medical facilities submit data on
new cancer diagnoses to a central cancer registry at the
state or territorial level. Both the data routinely collected
through cancer registries and the existing data collectionsevier Inc. on behalf of American Journal of Preventive Medicine.
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1. Summary of Data Items Collected by All Central
Cancer Registries
Data type
Examples of data
items collected
Record ID Registry identiﬁcation
Patient namea
Demographics Patient addressa
Race
Spanish/Hispanic origin
Sex
Date of birth
Cancer identiﬁcation Primary site
Histologic type (ICD-O-3)
Behavior code (ICD-O-3)
Grade
Date of diagnosis
Stage/Prognostic factors Stage
Tumor size
Treatment Type of ﬁrst course
of deﬁnitive treatment
Date of ﬁrst course
of deﬁnitive treatment
Follow-up/Recurrence/Death Date of last contact
Date of death
Underlying cause of death
aCDC does not receive patient identiﬁcation information.
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of cancer survivors, their physicians, and researchers.
The Dots: National Program of Cancer
Registries in Practice and Research
In 1992, Congress established the National Program of
Cancer Registries (NPCR) by enacting the Cancer
Registries Amendment Act, Public Law 102-515.5 Before
NPCR was established, ten states had no registry, and
most states with registries lacked the resources and
legislative support they needed to gather complete data.
Administered by CDC, NPCR funds 45 states, the
District of Columbia, Puerto Rico, and the U.S. Paciﬁc
Island Jurisdictions, which covers 96% of the U.S.
population.6 These central cancer registries collect data
on the occurrence of cancer, which includes the type,
extent (stage), and anatomic origin (primary site) of the
cancer (Table 1). Together, NPCR and the National
Cancer Institute’s Surveillance, Epidemiology, and End
Results (SEER) program7 collect data for the entire U.S.
population. Both NPCR and SEER use North American
Association of Cancer Registries standards and work
together to ensure compatibility and comparability of
U.S. cancer incidence, regardless of funding source.8
Using these data, CDC and the National Cancer Institute
publish annual data from both NPCR and SEER in the
U.S. Cancer Statistics Incidence and Mortality Web-
based Report.9 Although this online report hosts the
ofﬁcial federal cancer statistics of the U.S., NPCR and
SEER data are also made available through other online
tools, including CDC-WONDER,10 CDC’s Environmen-
tal Public Health Tracking Network,11 and State Cancer
Proﬁles.12 Additionally, NPCR analytic data are available
to researchers free through CDC’s National Center for
Health Statistics Research Data Center.13
Data collection occurs at the healthcare facility or
central cancer registry through medical record abstrac-
tion or electronic reporting. Incident cases from all
hospitals, physicians’ ofﬁces, pathology laboratories,
treatment facilities, and other medical facilities are
reportable to the central cancer registry. The goal of the
central cancer registry is to collect a standard set of data
on all cancer patients. Consequently, the data in the state
or territorial central registries represent everyone diag-
nosed or treated for cancer, regardless of race, age,
insurance status, or geography and are submitted to
NPCR or SEER on an annual basis. Because patient
populations and the infrastructure needs of each state
and territory are unique, central cancer registries vary in
the amount of funding they receive. A recent study
looking at ﬁve NPCR programs revealed that the cost per
cancer case ranged from $24 to $96 and the cost of dataDecember 2015enhancements and analysis ranged from $2.91 to $9.31
per case.14 However, despite these costs, the information
captured in the central registry is invaluable to cancer
surveillance and research and reﬂects real-world clinical
experiences of diverse populations in all medical care
settings.
A brief summary of the data items collected by all
central cancer registries is shown in Table 1. Because
these data items may come from different sources, and
patients often visit various healthcare providers during
their course of diagnosis and treatment, multiple health
facilities may be reporting information on the same
incident cancer. Although the central cancer registry is
responsible for case consolidation, CDC has several
surveillance informatics initiatives underway to identify
better ways to use emerging technology to incorporate
automated processes and electronic data exchange in
cancer reporting. Examples of these initiatives include
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central cancer registries using the encoded College of
American Pathologists Cancer Checklists and Health
Level Seven messages, and cancer reporting from ambu-
latory providers to registries in a new public health
objective for Stage 2 Meaningful Use.15
Additionally, the central cancer registry conducts data
linkages with state and national databases to supplement or
improve the data. Every central cancer registry routinely
links cancer data with that of its state death ﬁles, the
National Breast and Cervical Cancer Early Detection
Program, the National Death Index, and the Indian Health
Service. Some registries optionally link with other data
sources, such as Medicare and Medicaid claims ﬁles, to
address gaps identiﬁed in their data or improve the
usefulness of the data for local cancer control activities.
Together, NPCR and SEER form one of the most
sophisticated public health surveillance systems in the
U.S. and are the basis for nearly all cited cancer statistics
and projections, including the Annual Report to the
Nation on the Status of Cancer16–18 and the American
Cancer Society’s Cancer Facts & Figures.19 These routine
cancer surveillance activities are paramount to all cancer
research, including cancer survivorship research. In
addition to the routine cancer surveillance activities of
NPCR that provide incidence, mortality, and cancer
prevalence estimates for most of the U.S., CDC has a
number of initiatives underway speciﬁcally designed for
cancer survivorship research and care.Using Cancer Registries for Study
Recruitment
Central cancer registries are uniquely capable of provid-
ing population-based lists of all patients diagnosed with a
particular cancer for the purposes of research and health
interventions. Cancer registries strive to include all
cancer patients regardless of their SES, where they live,
and whether or not they received the best clinical care.
These real-world populations are invaluable in evaluating
the effectiveness of interventions, whether they are new
cancer treatments or behavior changes. Though state and
jurisdictional laws and regulations designed to protect
patient privacy dictate the availability and speciﬁc uses of
cancer registry data for research purposes, CDC has
undertaken a number of activities to help understand the
potential that NPCR registries have for such activities.Early Case Capture for Pediatric Cancer
Because of the complexity of cancer reporting and
required follow-up, reports to the central cancer registry
are often delayed beyond 6 months for reporting facilitiesto capture all diagnostic and treatment information on a
particular case. This delay at the registry level can often
limit the utility of such data for identiﬁcation and
recruitment of patients into clinical trials. In response
to this issue, and to the Carolyn Pryce Walker Act
(2008)20 that sought to improve the completeness and
timeliness of pediatric cancer tracking, CDC is piloting
an Early Case Capture project for pediatric cancer cases.
Seven NPCR registries are asking reporting facilities to
submit pediatric cases to them within 30 days of
diagnosis through this pilot, which has the potential to
lead to increased clinical trial enrollment and to accel-
erate other surveillance and research activities across the
cancer care continuum.21Behavioral Interventions
The use of population-based cancer registries for study
recruitment is a common practice in some states.22–30
However, for others, use of cancer registries for research
recruitment purposes is limited. Thus, CDC has recently
undertaken a number of initiatives to understand how it
can work at the federal level to facilitate and promote use
of cancer registries in these ways. In 2012, CDC funded a
3-year project through its Prevention Research Centers to
explore new ways that registry data could be used to
improve cancer screening among breast and colorectal
cancer survivors and their relatives. Funding was
awarded to three Prevention Research Centers to collab-
orate with their state cancer registries to accomplish this
goal: Emory University School of Public Health, Uni-
versity of Michigan School of Nursing, and the Univer-
sity of California at Los Angeles. Each center took a
unique approach and is currently analyzing its ﬁndings.
Overall, CDC found that although recruitment of survi-
vors was efﬁcient and effective using cancer registry data,
there were challenges to recruiting the family members of
survivors into studies. To continue use of cancer regis-
tries in the identiﬁcation and recruitment of people at
high risk of negative health outcomes, CDC has released
an announcement to fund an additional project in 2015
that would use cancer registry data to promote proactive
tobacco cessation (RFA-DP-15-008, SIP 15-003).Comparative Effectiveness and Patient-
Centered Outcomes Research
In 2010, CDC was awarded funding to support Com-
parative Effectiveness Research through the American
Recovery and Reinvestment Act of 2009. This project
established ten Specialized NPCR Registries to collect
enhanced data for people diagnosed in 2011 with breast
(n448,000), colon (n418,00), or rectum (n47,000)www.ajpmonline.org
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Information collected included all typically required
NPCR data elements and more-detailed information on
speciﬁc treatments, biomarkers/prognostic markers,
comorbid conditions, Census Tract–level SES measures,
and personal characteristics such as height and weight at
diagnosis (used to dose chemotherapy), smoking status,
and occupation as available. One goal of this project was
to examine population-based treatment patterns in
comparison to treatment guidelines. Over time, survival
will be compared between patients receiving different
treatments. These unique data will educate both pro-
viders and cancer survivors on treatment options,
practices, and potential barriers to delivery and receipt
of standards of care. Multiple analyses of these data are
currently underway by CDC and its state partners to
explore critical issues in cancer care, including guideline-
concordant use of biomarker testing and type of treat-
ment for breast and colorectal cancer by stage. As with all
NPCR data, these Comparative Effectiveness Research
data are available to researchers with the appropriate
human subject protection approvals through CDC’s
Research Data Center.
In 2013, CDC obtained additional support through a
Patient-Centered Outcomes Research Trust Fund award
via the Assistant Secretary for Planning and Evaluation to
collect intermediate outcomes such as progression,
recurrence, and vital status, as well as subsequent therapy
information on the same 2011 breast, colon, and rectum
cancer cases in ﬁve of the ten Specialized NPCR
Registries. A minimum of 32 months of follow-up will
be completed for these cases. Through active patient
follow-up, this effort will capture those with more
consistent aftercare visits versus those lost to follow-up
and better describe disease-free periods and time to
recurrence or progression. This information will provide
data on intermediate outcomes that are important to
cancer survivors and their providers, as well as traditional
survival statistics. In addition, these data will illustrate real-
world outcomes in a population that is more varied in age
and comorbid conditions than patients normally included in
clinical trials. On a population level, this will give researchers
a better understanding of disease course by site and stage
after completion of ﬁrst-course therapy. Once collected,
these data will also be made available through CDC’s
Research Data Center to improve the cancer community’s
understanding of population-level outcomes such as pro-
gression and recurrence for these speciﬁc cancers.
Treatment Summaries and Care Plans
In response to the 2005 IOM report,4 a number of expert
organizations have recommended that patients, alongDecember 2015with their primary care providers, receive from the
oncology team a summary of treatment provided as part
of a comprehensive survivorship care plan. Despite
limited evidence of their effectiveness, these plans are
now included in a number of cancer quality initia-
tives.14,32–34 Even with the increasing interest in survivor-
ship care plans, few recently diagnosed survivors report
receiving treatment summaries and written follow-up
instructions, and receipt of these documents varies
widely by subgroup.35,36
There are a number of challenges to cancer survivor-
ship care plan implementation. Provider barriers include
limited staff, time, and technologic resources to develop
and deliver the plans, lack of reimbursement and
information, and communication systems failing to
optimize communication and coordination of care.37
Patients with cancer often require treatment by multiple
specialists (surgeons, radiation oncologists, medical
oncologists) as part of multimodal therapies. As a result,
there is seldom a single integrated medical record, and
there may be limited formal written communication
between specialists.
To help reduce provider barriers to delivering cancer
survivorship care plans, CDC in collaboration with the
Colorado Central Cancer Registry recently developed a
secure, web-based application that allows individual
hospitals or providers to use previously collected cancer
surveillance data from the central cancer registry to pre-
populate and semi-automate care plans. The Web Plus
Survivorship Module includes templates for breast and
colorectal cancers, a generic template for all other
cancers, and a collection of static resource documents
covering general cancer information, physical activity,
nutrition, stress management, sexual health, and smok-
ing cessation. The module includes Spanish versions of
all templates and materials. The Colorado registry con-
ducted a pilot project with four hospital-based survivor-
ship programs and their staff oncologists to create
survivorship care plans using this tool. Oncology pro-
viders who developed and delivered the plans reported
high satisfaction with the web-based application in focus
groups. Patients also reported high satisfaction with the
care plans they received. CDC continues to work with the
Colorado Central Cancer Registry to integrate the tool
into Registry Plus™, a suite of publically available free
software programs developed and supported by CDC for
collecting and processing cancer registry data.38 Though
the Web Plus Survivorship Module is still in the ﬁnal
stages of beta testing, CDC is exploring expanding use of
the module to other NPCR cancer registries as well as
development of new content for additional cancer types.
Although the completeness and timeliness of data
collected through cancer registries may limit the
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plans, at least some of the data needed by the clinician
compiling a care plan will be available in the registry.
This project demonstrates innovative use of routinely
collected registry data to inform cancer survivors about
their cancer diagnosis, the care they have received, and
expectations for their next steps and future care. It also
helps healthcare providers develop and deliver survivor-
ship care plans that meet requirements of initiatives
meant to improve the quality of cancer care. This project
leverages resources, using previously collected data from
the central cancer registry to reach out to community
oncologists and primary care providers to illustrate how
the registries can help them improve communications
and efﬁciencies in meeting the needs of cancer survivors.
The multidirectional sharing of health information as
demonstrated in this project has tremendous potential
and applicability not only for cancer registries and
survivorship care, but also for other disease registries.
CDC plans to continue this initiative with the goals of
facilitating the integration of this system into existing
physician workﬂows for interested hospitals or vendors,
exchanging structured data across systems, and leverag-
ing existing tools to allow patients to access all their
health information, treatment summary, and survivor-
ship care plan electronically.Connecting the Dots to Create a Picture of
Quality Survivorship Care for Patients and
Populations—A Vision for the Future
The NPCR cancer registries face a number of barriers
and challenges to collecting, maintaining, and dissem-
inating the most useful data for public health surveillance
and research. Existing legal and regulatory requirements
often dictate the availability and use of certain data.
Registry data collection is traditionally limited by the
type of data available in medical records. Finally, the
availability of resources (e.g., ﬁnancial, personnel, infor-
mation technology) at the national, state/territorial, and
local levels also constrain the capabilities of cancer
registries. However, if cancer registries can ﬁnd ways to
overcome these barriers, they have tremendous potential
to improve quality cancer survivorship care.Applying Registry Data for Quality Assessment and
Improvement
Given the registry systems and processes that form an
infrastructure for cancer surveillance, the potential to
link these “dots” to promote quality survivorship care
and research is promising. Take the data for a given
breast cancer patient, “Ms. P.” Information about Ms. Pand her cancer diagnosis is reported to a central cancer
registry. These data are available for epidemiologic and
population surveillance studies—the traditional applica-
tions of the registry system. However, the Web Plus
Survivorship Module project demonstrates how these
data can also be used to improve Ms. P’s care directly by
facilitating completion of her survivorship care plan. This
contributes to her care by making it possible, or at a
minimum easier, to provide her with a cancer survivor-
ship care plan.
In addition to being used directly in an individual
patient’s care, the registry data aggregated across patients
provide useful information on patterns of care and
outcomes. For example, the American Society for Clin-
ical Oncology piloted a registry for survivorship care plan
data in which 20 practices entered data on 2,014 newly
diagnosed breast cancer patients.39 These data were used
to populate treatment plans and summaries and could be
used to produce practice-speciﬁc and aggregate quality
measures (e.g., the proportion of eligible women pre-
scribed adjuvant hormone therapy). The comparative
effectiveness and patient-centered outcomes work con-
ducted by CDC through NPCR is another example of
how registries can be used to evaluate quality of care
through collection and consolidation of treatment data
and outcomes.
Evaluations of care quality can, in turn, guide quality
improvement initiatives. Though not a registry, per se,
the Quality Oncology Practice Initiative (QOPI) provides
an example of how this could work.34 QOPI is a
voluntary system for oncology practices to report their
performance on a number of quality indicators, and as
illustrated by Blayney et al.,40 the reporting and bench-
marking information helped inform quality improve-
ment at the University of Michigan Comprehensive
Cancer Center. The QOPI data showed that an above-
average percentage of cancer patients at the University of
Michigan were receiving chemotherapy during the last 2
weeks of life. After these data were provided to the faculty
oncologists, this number decreased from approximately
50% to 20%.Linking Registry Data with Patient-Reported
Outcomes to Make Care and Research More
Patient-Centered
Although clinical data abstracted from medical records
provide important information on patterns of care and
outcomes, these data become more powerful when linked
with the patient perspective, measured via patient-
reported outcomes (PROs).41 PROs are reports directly
from the patient about health, disease, or treatment,
without amendment or interpretation by a clinician orwww.ajpmonline.org
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symptoms, functioning, treatment satisfaction, and
health-related quality of life, among other measures.42,43
PROs are increasingly being incorporated in electronic
health records,44 expanding their availability for clinical
care and research.
Imagine that throughout her cancer treatment, Ms. P
completed a brief questionnaire that covered her func-
tioning, well-being, and symptoms. This PRO reporting
system might help her clinician identify and address
Ms. P’s anxiety stemming from her cancer. This infor-
mation could be included in her survivorship care plan to
advise her primary care provider that this issue requires
monitoring and potential management. In fact, quite a
few electronic systems have been developed for this
purpose of assessing PROs in practice.45 Again, these
data become more powerful when linked with other
clinical information, such as an electronic health record,
a cancer registry, or clinical trials.41 For example, QOPI is
planning to pilot PRO quality indicators to make its
quality reporting system more patient-centered.46 Sim-
ilarly, the SEER registry data for Medicare Advantage
beneﬁciaries has been linked with the Medicare Health
Outcomes Survey, thereby linking registry data with PRO
data.47 Rather than linking the PRO and registry data
after data have been submitted, patient portals, such as
the electronic PRO reporting systems described above,
could be used to enter the PRO data directly into the
registry database. Though many signiﬁcant challenges
exist for collecting PROs through cancer registries, such
as limitations in local legislation, working toward ena-
bling a more ﬂuid data exchange process among patients,
clinicians, healthcare facilities and the central cancer
registry would allow for better health communication
and immediate outcomes, as well as improving the
timeliness of cancer research and surveillance.
Connecting the dots of the PRO and clinical infor-
mation creates a powerful platform for a learning
healthcare system. In IOM’s 2013 publication, “Best
Care at Lower Cost: The Path to Continuously Learning
Health Care in America,” a learning healthcare system
is one that uses advances in computing, information
science, and connectivity to improve communication
between the patient and clinician, point-of-care guid-
ance, the capture of experience, population surveil-
lance, planning and evaluation, and the application of
real-time knowledge.48 Though not necessarily popu-
lation-based, such a system would enable examination
of cancer survivorship issues such as the rates of
moderate/severe nausea associated with different che-
motherapy regimens under real-world practice condi-
tions, the long-term impact on cognitive function of
different doses of radiation to the brain, or the impactDecember 2015of treatments on sexual function. The American Society
for Clinical Oncology’s CancerLinQ is being developed
for this purpose.49 Its long-term goal is to provide real-
time quality feedback and decision support while
analyzing patterns of care.49 When PROs are linked
to, or included in, electronic health records or regis-
tries, they provide essential information from the
patient perspective to these learning health systems,
enabling new information from the cancer care expe-
rience to inform the biomedical knowledge base.
Conclusions
Cancer surveillance data remain the core of cancer
epidemiology and outcomes in clinical cancer research.
Cancer registries are among the most sophisticated and
standardized surveillance systems in the U.S. and have
been used as a reputable source of surveillance, epidemi-
ology, or comparative effectiveness/patient-centered out-
comes research data for decades. Whether for
repurposing public health surveillance data to aid directly
in patient care or for contributing to the understanding
of how cancer treatments inﬂuence population health,
cancer registries are uniquely poised to serve as a source
of critical data for cancer survivors, clinicians, and
researchers.
As a leader in the development of policies and
methodologies for collecting complex clinical data more
rapidly through electronic advances, CDC manages
NPCR in a health data environment that is swiftly
changing. To remain at the forefront of clinical and
epidemiologic research, NPCR registries will continue to
expand their usefulness to cancer survivors, providers,
and researchers—and enhance the infrastructure for
rapid reporting of incident cancer cases while simulta-
neously acknowledging the importance of capturing
more-complete treatment data.
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